Carisma Therapeutics inks $53 mln Series A
Philadelphia-based Carisma Therapeutics Inc, a developer of macrophage-based immunotherapeutics, has raised $53 million in Series A financing. AbbVie Ventures and HealthCap led the round with participation from other investors that included IP Group, Penn Medicine, Grazia Equity, Wellington Partners, TPG Biotech, MRL Ventures Fund and Agent Capital.
27 June 2018•1 min read
